Furiex Pharma (FURX) Will Present Eluxadoline Phase III Data at Late-Breaking Abstract Session at DDW 2014
Tweet Send to a Friend
Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) announced that results from its two Phase III clinical trials of eluxadoline in patients with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
